Overview of recall records associated with Boehringer Ingelheim Roxane Inc., including dates, categories and classifications where available.
Classification mix: Class III: 2, Class II: 2.
CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP.
CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP.
Defective Delivery System: Inhalers do not spray properly, emitting either no spray or a short transient spray.
Subpotent Drug: The firm received an out of specification result for Assay (potency was below specification) at the 9 month stability time point.
This page summarizes recall records in which the official source identifies Boehringer Ingelheim Roxane Inc. as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.
